OncoPredikt Test
Rapid AI/ML based testing of genomic signatures such as HRD, MSI, TMB and PDL1
OncoPredikt-HRD is an AI-based patient selection tool which can predict HRD status using whole slide imaging analysis of the diagnostic H&E slide to identify all key biomarkers involved to screen for patient candidates likely to benefit from PARPi therapy before they undergo expensive and time-consuming NGS testing
OncoPredikt-IO is an AI-based patient selection tool which has been trained to identify key genomic signatures for Immunooncology from Whole Slide H&E images to more definitively identify patients who should undergo NGS testing and are likely to benefit from these tests. The key biomarkers identified using our AE-based model are:
• Microsatellite Instability (MSI)
• Tumor Mutational Burden (TMB
• Microsatellite Instability (MSI)
• Tumor Mutational Burden (TMB